يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Tesileanu, C Mircea S"', وقت الاستعلام: 1.53s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

    المؤلفون: van den Bent, Martin J, Tesileanu, C Mircea S, Wick, Wolfgang, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Erridge, Sarah, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-François, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà , Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, de Heer, Iris, Aldape, Kenneth, Jenkins, Robert B, Dubbink, Hendrikus Jan, Kros, Johan M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, French, Pim, Baumert, Brigitta G

    المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer

    المصدر: The Lancet. Oncology, Vol. 22, no.6, p. 813-823 (2021)

    مصطلحات موضوعية: Adolescent, Adult, Aged, Australia, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 1, Pair 19, Combined Modality Therapy, Dacarbazine, Europe, Female, Glioma, Humans, Isocitrate Dehydrogenase, Loss of Heterozygosity, Male, Middle Aged, North America, Radiotherapy, Conformal, Temozolomide, Young Adult

    العلاقة: boreal:264022; http://hdl.handle.net/2078.1/264022Test; info:pmid/34000245; urn:ISSN:1470-2045; urn:EISSN:1474-5488

    الإتاحة: https://doi.org/10.1016/S1470-2045Test(21)00090-5
    http://hdl.handle.net/2078.1/264022Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

    المؤلفون: van den Bent, Martin J, Tesileanu, C Mircea S, Wick, Wolfgang, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Erridge, Sarah, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-François, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà , Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, de Heer, Iris, Aldape, Kenneth, Jenkins, Robert B, Dubbink, Hendrikus Jan, Kros, Johan M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, French, Pim, Baumert, Brigitta G

    المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer

    المصدر: The Lancet. Oncology, Vol. 22, no.6, p. 813-823 (2021)

    مصطلحات موضوعية: Adolescent, Adult, Aged, Australia, Chemotherapy, Adjuvant, Chromosomes, Human, Pair 1, Pair 19, Combined Modality Therapy, Dacarbazine, Europe, Female, Glioma, Humans, Isocitrate Dehydrogenase, Loss of Heterozygosity, Male, Middle Aged, North America, Radiotherapy, Conformal, Temozolomide, Young Adult

    العلاقة: boreal:264022; http://hdl.handle.net/2078.1/264022Test; info:pmid/34000245; urn:ISSN:1470-2045; urn:EISSN:1474-5488

    الإتاحة: https://doi.org/10.1016/S1470-2045Test(21)00090-5
    http://hdl.handle.net/2078.1/264022Test

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث